Hazchem,Hospira kicked in money for Europe because Europe is the...

Hazchem,

Hospira kicked in money for Europe because Europe is the largest market for CML, with about 60,000 CML patients (see link below). As t315i patients are a small % of the total CML population, the larger the CML population, the larger the t315i population. Read too many analyst reports that quote the USA as the largest market!

http://www.medicalnewstoday.com/articles/125886.php

USA is smaller market with only 25,000 CML patients (CXS source), hence the number of t315i patients are smaller. The FDA ODAC panel member estimated about 200-300 patients per year - alot smaller than company estimates of 2500.

Jack - re the ODAC panel link - I have posted it previously in a post titled 't315i market'.

JM2002au - the stats you quote come from the company and 1 publication. If you are happy to listen to everything the company tells you, then good for you. But for those that want to do their own due diligence - those stats do not add up to what the FDA says...There are 5000 new CML cases per year in USA.

http://www.leukemia.org/all_page?item_id=9346 If 15-20%

15-20% of t315i mutations would mean (15-20% x 5000) = 750-1000 new t315i patients per year in USA.

The FDA quote 200-300 per year in USA.

Do the maths on the quoted FDA numbers and see what valuation it justifies.

Diersel - the docs tell me that t35i mutations are heterogenous in population, and so TKI will still work to a limited degree depending on how many cells have the t315i mutation. Only in homogenous t315i populations due TKI have no response at all and hence would be put on Omapro. But hey, dont trust me, ask the experts!

End of the day, these are just my opinions. Please come to your own conclusions. I hope for the patients that this treatment becomes readily available.